PAGITANE Drug Patent Profile
✉ Email this page to a colleague
When do Pagitane patents expire, and what generic alternatives are available?
Pagitane is a drug marketed by Lilly and is included in one NDA.
The generic ingredient in PAGITANE is cycrimine hydrochloride. Additional details are available on the cycrimine hydrochloride profile page.
Summary for PAGITANE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 24 |
Patent Applications: | 58 |
DailyMed Link: | PAGITANE at DailyMed |
US Patents and Regulatory Information for PAGITANE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lilly | PAGITANE | cycrimine hydrochloride | TABLET;ORAL | 008951-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Lilly | PAGITANE | cycrimine hydrochloride | TABLET;ORAL | 008951-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |